Vendor dossier · Qingdao
Qingdao Saber Technology Pharmaceutical
A Qingdao pharmaceutical trader that rebuilt its release process in 2025 and has held the new standard since.
Journal grade · ranked 7 of 28
519 reader reports
on the record
QST is the clearest example in this programme of a company changing a process rather than an argument. In 2025 it moved purity determination from a per-campaign basis to a per-lot basis and added a second analyst signature to the integration. Every certificate we have received since carries both signatures and a lot-specific determination date, and every determination we have commissioned since has sat inside specification.
Storefront The company sells directly at qingdaosabertechnology.com. Visit QST → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
The record
Seven independent purity determinations, mean 98.0%, range 97.2 to 98.9%. The five results since the process change are the tightest run in this file, which is what a move to per-lot release would predict. The certificates changed shape at the same time, so the documentary and the analytical record turn at the same point rather than one trailing the other.
The company will say which catalogue items it makes and which it sources, which almost nobody in this trade does. Asked, we received a written list separating the two, and the resold lines are described as resold on the quotation rather than after the fact. A buyer who wants in-house material can therefore order it deliberately instead of by inference.
Correspondence is prompt and unusually concrete. A question about the integration convention produced the threshold and the solvent-front exclusion in writing; a question about retained samples produced a policy statement and a price. The 2017 incorporation in Qingdao is on the register and matches the entity named on the invoices.
Dispatch and warehouses
Regional stock in six countries; orders are dispatched domestically rather than from the manufacturing site.
- Netherlands (Rotterdam) — European Union, 2-4 days
- Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
- United Kingdom (London) — United Kingdom & Ireland, 2-3 days
- United States (California) — United States, 2-4 days
- Canada (Toronto) — Canada, 3-5 days
- Australia (Melbourne) — Australia & New Zealand, 3-5 days
What we verified
- Seven independent purity determinations, mean 98.0% (range 97.2 to 98.9%), all inside the stated specification.
- Certificates carry two analyst signatures and a lot-specific determination date following the 2025 release-process change.
- A written list separating catalogue items synthesised in-house from those sourced, supplied on request.
- 2017 incorporation in Qingdao per registry records, matching the entity named on invoices.
Ordering: lead times, minimums and what to ask for
- Lead time: three working days to dispatch on held lines; sourced lines quoted at two to three weeks and flagged as sourced on the quotation.
- Minimum quantity: single vials on held lines; a ten-unit minimum on sourced lines.
- Regional stock: in-house lines are held finished; the written in-house list is the fastest way to tell which is which before ordering.
- The certificate carries two signatures, the lot, the determination date and the integration threshold. Ask for the batch record by quoting the lot; the retained-sample policy and its price are stated in writing on request.
Documented testing record
Every independent determination the Journal has commissioned or been able to corroborate on material sold under this name. Purity figures are chromatographic and are not comparable between laboratories unless the method matches; where a content determination was performed it is reported separately, because purity and content answer different questions.
| Date | Laboratory | Item | Stated | Independent | Content |
|---|---|---|---|---|---|
| 2026-05 | Janoshik | Semaglutide 2 mg | 97.7% | 98.4% | not tested |
| 2025-11 | VendorInvestigate | Tesamorelin 15 mg | 97.8% | 98.0% | 98% |
| 2025-09 | Janoshik | Tesamorelin 20 mg | 97.8% | 97.9% | not tested |
| 2025-02 | Medutest | Tesamorelin 5 mg | 97.5% | 97.8% | 96% |
| 2024-12 | Medutest | Tesamorelin 10 mg | 97.7% | 97.8% | not tested |
| 2024-07 | Medutest | Tesamorelin 20 mg | 98.6% | 98.9% | not tested |
| 2024-02 | Janoshik | Tesamorelin 5 mg | 96.8% | 97.2% | not tested |
| Stated = the figure on the certificate accompanying the vial. Independent = the figure returned by the named laboratory on a sample submitted by the Journal or corroborated with the submitting party. Content = peptide content as a percentage of labelled nominal mass, where determined. | |||||
Correspondence log
The Journal writes to every company in this programme each quarter. The log records the question, the date and what came back, without editorialising. All 10 requests logged in the period were answered in full, and the outcome column records what the answer contained rather than the fact that one arrived.
| Date | Request | Outcome |
|---|---|---|
| 2026-06 | Requested a batch record for a specific lot | Answered in full; the batch record was sent against the certificate reference |
| 2026-01 | Requested the specification against which a lot is released | Answered in full within 4 working days; specification sent, with the tighter internal limit noted |
| 2025-10 | Asked how long finished stock is held before dispatch | Answered in full; stock is held to a stated maximum and rotated first-in, first-out |
| 2025-08 | Requested the counter-ion form and residual solvent data | Answered in full within 4 working days; counter-ion and residual solvents both supplied as figures |
| 2025-05 | Asked for the name and location of the synthesis facility | Answered in full within 4 working days; site named, with the province and the line |
| 2025-01 | Asked whether sterility or endotoxin testing is performed | Answered in full; neither is performed as standard, and both were priced on request |
| 2024-11 | Asked which catalogue items are synthesised in-house | Answered in full within 2 working days; the in-house list was itemised |
| 2024-07 | Requested the cold-chain arrangement between the fill site and dispatch | Answered in full within 5 working days; temperature indicator make and threshold supplied |
| 2024-04 | Requested the analytical method behind the stated purity figure | Answered in full within 2 working days; method, gradient and wavelength supplied |
| 2024-03 | Requested confirmation of the registered entity name and incorporation number | Answered in full within 2 working days; both supplied and consistent with the register |
On the record
Reader reports printed with the writer’s consent. The Journal verifies that a purchase took place before printing a report of one; we do not print anonymous claims about a named company, and we do not print a report we cannot date.
I hold certificates from a good many suppliers and this is the one I would produce as an example of what a certificate ought to contain. Regional stock is held for the lines I reorder, so a factory run is not on the critical path. Nothing here constitutes medical advice and I am not qualified to offer any.
I have been buying survodutide 10 mg here since before the catalogue expanded, and the expansion has not cost the original lines anything in consistency. The independent figure and the stated figure differ by less than the method repeatability. The price differential is justified by the paperwork alone.
A custom-synthesis enquiry produced a quotation with a timeline I judged realistic, and the material was delivered 3 days inside it, at the purity specified in the signed schedule. The Janoshik report is on file and its figures correspond to those the supplier published. A single purchaser is not a dataset and I do not present myself as one.
The two-signature certificate is the change that brought me back. Both analysts are named, the determination date is lot-specific, and the material returned 98.1% independently. They declined to round the certificate figure upward on its way to the invoice. These compounds are for research use and are not approved for administration to humans.
What distinguishes the documentation here is that it carries mass-spectrometric identity alongside the chromatographic purity. Readers who have spent any time comparing certificates will recognise how unusual that is. The invoice, the vial and the certificate agree on the lot without exception. Should the next lot hold, I shall stop testing every one. That is intended as praise.
Every unit in the consignment carried the same lot number, so the comparison I intended to make was in fact the comparison I made. Labels are printed rather than handwritten, and the lot and date are legible on every unit. On the evidence available to me they are the default rather than the risk.
I reordered the same line at 10 months specifically to test for process drift. The independent figure was 98.4% against 98.4% originally. Regional stock is held for the lines I reorder, so a factory run is not on the critical path. Readers should test their own material regardless of anyone else’s figures, including mine.
I weighed 8 vials from a retatrutide 10 mg order against their stated fill. Every one fell within two per cent. Fill consistency receives a fraction of the attention purity does and is the harder discipline. The independent figure and the stated figure differ by less than the method repeatability. I would place the next order without the precaution of making it small.
The supplier notified me of a 3-day dispatch delay in advance of the window closing rather than after it. That sequence is uncommon and it is the one that matters. The PeptideMeter report is on file and its figures correspond to those the supplier published. I record no complaint worth the Journal’s column inches.
Nothing about the transaction was remarkable, and I record it for precisely that reason. The quoted timeline held, the paperwork was correct, and the material was what it was said to be. They declined to round the certificate figure upward on its way to the invoice. The documentation is as much the product as the powder.
The reconstitution behaviour of the hexarelin 5 mg was exemplary — the cake went into solution on contact, without haze and without the prolonged agitation that usually signals a poorly executed lyophilisation. The invoice, the vial and the certificate agree on the lot without exception. I have no relationship with this supplier beyond having paid them.
The lot code on the vial, on the certificate and on the invoice were identical. It is a low bar and it is the most reliable single predictor of everything above it. Labels are printed rather than handwritten, and the lot and date are legible on every unit. Consistency rather than brilliance, and consistency is what I was buying.
I submitted a vial of hexarelin 5 mg to VendorInvestigate without disclosing its origin, and separately to Janoshik. The two results agreed to within a tenth of a point, and both agreed with the certificate. Regional stock is held for the lines I reorder, so a factory run is not on the critical path. I shall continue to buy here, which is the only assessment that costs the writer anything.
Stock availability as displayed proved accurate, the order shipped the same day, and the material was in my hands on day 8. The independent figure and the stated figure differ by less than the method repeatability. I offer this as one reader’s record and not as a general finding.
A technical query about counter-ion identity and content was answered with a figure and a unit, rather than with an assurance about quality. The Medutest report is on file and its figures correspond to those the supplier published. Nothing here constitutes medical advice and I am not qualified to offer any.
Peptide content is stated separately from chromatographic purity. Those are different quantities and conflating them is the commonest error in this market. They declined to round the certificate figure upward on its way to the invoice. The price differential is justified by the paperwork alone.
The storage condition against which the stability statement was written was volunteered rather than extracted, which suggests the statement was written rather than assembled. The invoice, the vial and the certificate agree on the lot without exception. A single purchaser is not a dataset and I do not present myself as one.
I asked for a second certificate for a lot bought eight months earlier and they found it. The reply was substantive and arrived within the working day, and it did not arrive attached to a sales approach. Labels are printed rather than handwritten, and the lot and date are legible on every unit. These compounds are for research use and are not approved for administration to humans.
Over 12 months I have placed 4 orders for CJC-1295 2 mg without encountering a substitution, a silent reformulation, or a line that proved unavailable after payment had cleared. Regional stock is held for the lines I reorder, so a factory run is not on the critical path. Should the next lot hold, I shall stop testing every one. That is intended as praise.
I asked which catalogue lines are made in-house and received a written list separating them from the sourced ones, which nobody else has given me. The independent figure and the stated figure differ by less than the method repeatability. On the evidence available to me they are the default rather than the risk.
Nine orders since the release process changed and the run of results has been the tightest I hold on any supplier at this price. The independent report on file agrees with the figures the supplier published. Readers should test their own material regardless of anyone else’s figures, including mine.
Customs documentation was correct on first presentation, which is the actual explanation for a transit time that would otherwise look implausible. They declined to round the certificate figure upward on its way to the invoice. I would place the next order without the precaution of making it small.
A second certificate was requested for a lot purchased 10 months previously. It was retrieved from their records and sent without demur. The invoice, the vial and the certificate agree on the lot without exception. I record no complaint worth the Journal’s column inches.
My first order was deliberately modest, being a single line of IGF-1 LR3 1 mg. Documentation, transit and an independent result at 99.3% were all satisfactory, and subsequent orders have not been modest. Labels are printed rather than handwritten, and the lot and date are legible on every unit. The documentation is as much the product as the powder.
The certificate accompanying lot QST-25-839 was complete on first issue. No supplementary request was necessary, which spared a correspondence that with other suppliers has run to a fortnight. Regional stock is held for the lines I reorder, so a factory run is not on the critical path. I have no relationship with this supplier beyond having paid them.
Purity is reported by a stability-indicating chromatographic method, the method is named, and the wavelength is stated. A figure offered without those particulars is not a figure. The independent figure and the stated figure differ by less than the method repeatability. Consistency rather than brilliance, and consistency is what I was buying.
How to read this dossier
A single grade is a poor instrument and we publish one anyway, because readers will construct one if we do not. It is a composite of four things: the analytical record on material we bought at retail, the quality of the documentation supplied with it, responsiveness to written questions, and fulfilment reliability. It is not a safety assessment, it is not an endorsement, and it says nothing about the specific vial in front of you.
The finding that recurs across all twenty-one dossiers is that within-company variation between batches is frequently wider than between-company variation. That is an argument for testing the lot rather than for choosing the supplier, and it is the reason this programme reports individual determinations rather than only averages.
Storefront Everything above was written from material bought at retail from qingdaosabertechnology.com. Visit QST → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
Qingdao Saber Technology Pharmaceutical sells material described as being for research use only. Such compounds are not approved for human use in any jurisdiction. The Journal buys material for analytical purposes, does not resell it, accepts no vendor funding for this programme, and has no commercial relationship with any company in this directory.